Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.32 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24022690 | 0.94 | KDM4E (0.40) | KDM4EALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL24022698 | 0.80 | KDM4E (0.43) | KDM4EALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL23130659 | 0.80 | LMNA (0.39) | KDM4EALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL18790076 | 0.77 | HSP90AB1 (0.39) | HSP90AA1HSP90AB1 | |
| SCHEMBL10647409 | 0.75 | POLB (0.48) | ALDH1A1LMNAMAPT | |
| SCHEMBL24022696 | 0.74 | KDM4E (0.59) | KDM4EALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL13009780 | 0.72 | HSP90AB1 (0.39) | HSP90AA1HSP90AB1 | |
| SCHEMBL24348446 | 0.71 | MAPK1 (0.38) | KDM4EALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL17365268 | 0.71 | ALDH1A1 (0.41) | ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL23207798 | 0.70 | CXCL12 (0.47) | KDM4EALDH1A1LMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872546-B2 | Catalyst for hydrogenation reaction and method for producing same | LG CHEM, LTD. (KR) | 2024-01-16 | — | — | US | disclosed |
| US-20220118432-A1 | CATALYST FOR HYDROGENATION REACTION AND METHOD FOR PRODUCING SAME | LG CHEM, LTD. (KR) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118432-A1 | CATALYST FOR HYDROGENATION REACTION AND METHOD FOR PRODUCING SAME | GRHPR, HAO2, HACL2 | KDM4E 3249/4885ALDH1A1 2211/4885LMNA 4748/4885 |
| US-11872546-B2 | Catalyst for hydrogenation reaction and method for producing same | GRHPR, HAO2, HACL2 | KDM4E 3249/4885ALDH1A1 2211/4885LMNA 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.